Quantcast
Last updated on April 20, 2014 at 21:20 EDT

NxStage® System One(TM) Patients to Participate in 220 Mile Bike Ride to Raise Awareness of Kidney Disease

September 12, 2013

System One provides riders flexibility to dialyze during three-day biking event

LAWRENCE, Mass., Sept. 12, 2013 /PRNewswire/ — NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that three NxStage System One home hemodialysis patients and four NxStage managers are participating in the 2013 Tour DaVita. Now in its seventh year, this year’s event is a three-day, 220 mile bike ride through South Carolina starting on September 14, 2013.

(Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO )

Tour DaVita, which receives support from NxStage, is an annual ride that raises awareness and funds for the fight against kidney disease. This year, 600 members of the kidney community, including three NxStage patients and four NxStage managers, are participating in the ride. All funds are donated to The Kidney TRUST, an organization that provides free kidney health screening to the public in non-medical settings.

Highlighting the portability and flexibility of the System One, NxStage patients plan to perform their dialysis treatments along the race route in an RV.

Jan Morrow, a NxStage patient since 2010, is excited to be participating in this year’s tour. “I have always been an active person, but after my doctor said I was in kidney failure, I never imagined I would have the energy to keep up,” she said. “Not only can I run again, I am thrilled to be riding in my first bike event alongside other patients and my home dialysis nurse.”

“We are all greatly inspired by the passion and commitment of our patients, staff and others that participate in this physically demanding event to raise awareness of kidney disease,” said Jeffrey Burbank, Chief Executive Officer, NxStage Medical, Inc. “We proudly support their efforts to ensure that patients have access to information and high-quality renal therapy, including more frequent home hemodialysis.”

About the NxStage System One

The NxStage System One is the first and only truly portable hemodialysis system cleared for home use by the U.S. Food & Drug Administration (FDA). Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients’ homes and give patients the freedom to travel with their therapy. When combined with the NxStage Pureflow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, at home or on vacation. http://www.nxstage.com/.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company’s website at www.nxstage.com.

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words “anticipate,” “believe,” “expect,” “estimate,” “plan,” and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage’s filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2013. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Kristen K. Sheppard, Esq.
VP, Investor Relations
ksheppard@nxstage.com

SOURCE NxStage Medical, Inc.


Source: PR Newswire